<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="project_funders\PMC6080746\results\search\funders\results.xml">
  <result pre="Trials : Medicine and Health Sciences : Pharmacology : Drug" exact="Research and Development" post=": Clinical Trials: Cluster Trials : Research and Analysis"/>
  <result pre="KahnRebecca1http://orcid.org/0000-0003-1117-1975RidAnnette2http://orcid.org/0000-0003-0080-7560SmithPeter G.3http://orcid.org/0000-0003-1056-6609EyalNir4http://orcid.org/0000-0003-1504-9213LipsitchMarc15*[1], Center for Communicable Disease Dynamics, Department of Epidemiology," exact="Harvard T.H. Chan School of Public Health," post="Boston, Massachusetts, United States of America[2], Department of Global"/>
  <result pre="States of America[2], Department of Global Health &amp;amp; Social Medicine," exact="King’s College London," post="London, United Kingdom[3], MRC Tropical Epidemiology Group, London School"/>
  <result pre="Medicine, London, United Kingdom[4], Department of Global Health and Population," exact="Harvard T.H. Chan School of Public Health," post="Boston, Massachusetts, United States of America[5], Department of Immunology"/>
  <result pre="United States of America[5], Department of Immunology and Infectious Diseases," exact="Harvard T.H. Chan School of Public Health," post="Boston, Massachusetts, United States of America I have read"/>
  <result pre="Pfizer, Merck, Affinivax, and Antigen Discovery and research grants from" exact="Pfizer" post="and PATH Vaccine Solutions. * E-mail: mlipsitc@hsph.harvard.edu epub: 2018-8-8collection:"/>
  <result pre="Affinivax, and Antigen Discovery and research grants from Pfizer and" exact="PATH" post="Vaccine Solutions. * E-mail: mlipsitc@hsph.harvard.edu epub: 2018-8-8collection: 2018-8158e1002632(C) Kahn"/>
  <result pre="This work was supported by award number U54GM088558 from the" exact="National Institute of General Medical Sciences," post="as well as by grant 208766/Z/17/Z from Wellcome/VW/RB. The"/>
  <result pre="Wellcome grant 201249/Z/16/Z. PGS is partly supported by the UK" exact="Medical Research Council" post="(MRC) and the UK Department for International Development (DFID)"/>
  <result pre="by the UK Medical Research Council (MRC) and the UK" exact="Department for International Development" post="(DFID) under the MRC/DFID Concordat agreement and is also"/>
  <result pre="effective, to deploy them. Following the 2014–2016 Ebola epidemic, the" exact="World Health Organization" post="(WHO), the Coalition for Epidemic Preparedness Innovations, and other"/>
  <result pre="an online interactive decision tool as part of the WHO" exact="Research and Development" post="Blueprint for Action to Prevent Epidemics (the InterVax-Tool: http://vaxeval.com/)"/>
  <result pre="and does not necessarily represent the official views of the" exact="National Institute of General Medical Sciences" post="or the National Institutes of Health. Provenance: Not commissioned;"/>
  <result pre="of the National Institute of General Medical Sciences or the" exact="National Institutes of Health." post="Provenance: Not commissioned; externally peer-reviewed Abbreviations cRCT cluster-randomized controlled"/>
  <result pre="Sierra Leone Trial to Introduce a Vaccine Against Ebola WHO" exact="World Health Organization" post="References References 1BrendeB, FarrarJ, GashumbaD, MoedasC, MundelT, ShiozakiY, et"/>
  <result pre="pathogens. WHO workshop on prioritization of pathogens report. 2015. 3collab:" exact="National Academy of Sciences" post="Engineering and Medicine. Integrating clinical research into epidemic response:"/>
  <result pre="immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California" exact="Kaiser Permanente" post="Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:"/>
 </snippets>
</snippetsTree>
